KEYTRUDA + Chemo Significantly Improved OS vs chemo Alone in With HER2-Neg Gastric or GEJ Adenocarcinoma Patients Regardless of PD-L1 Expression
“Most gastric cancers go undetected until an advanced stage, at which point the five-year survival rate is just 6%, one of the lowest across cancer types,” said Dr. Sun Young Rha, director and professor of medical oncology in the Department of Internal Medicine, Songdang Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea. “The positive overall survival results observed in this study are very encouraging and demonstrate the potential of KEYTRUDA in combination with chemotherapy to extend the lives of patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.”
Share:
More News
PharmaMar has submitted a Marketing Authorization Application to the European Medicines Agency for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer, whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. The MAA submission
“At SR One, our mission is to invest in companies that we believe have the ability to innovate and advance transformational new therapies in areas of high unmet medical need,” said Simeon George, M.D., Chief Executive Officer and Managing Partner at SR One. “Fore Bio is focused on resetting the
The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of TACE-progression-free survival (TACE PFS*), and the other primary endpoint of overall survival (OS) is immature at the prespecified first interim analysis. Meanwhile, a clinically meaningful PFS by RECIST v1.1** was also observed. Detailed findings from
“The positive CHMP recommendation for the Itovebi-based regimen represents a significant step towards providing people in the EU with PIK3CA-mutated, ER-positive advanced breast cancer with a targeted therapy in the first-line setting,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This recommendation is
